Scarica l'app Stockscreener
55.60
2.53%
1.37
Dopo l'orario di chiusura:
55.53
-0.07
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$54.23
Aprire:
$55.4
Volume 24 ore:
3.50M
Relative Volume:
0.37
Capitalizzazione di mercato:
$22.05B
Reddito:
$1.94B
Utile/perdita netta:
$-2.82B
Rapporto P/E:
-7.6566
EPS:
-7.2617
Flusso di cassa netto:
$-2.08B
1 W Prestazione:
+2.47%
1M Prestazione:
+8.21%
6M Prestazione:
+107.08%
1 anno Prestazione:
+116.01%
Intervallo 1D:
$54.35
$55.93
Intervallo di 1 settimana:
$51.68
$56.20
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
55.60 | 21.51B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
437.67 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.58 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.22 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.58 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.41 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - BioPharma Dive
European Commission Approves MRNA's COVID-19-Influenza Combo Shot - Yahoo Finance
Moderna starts late-stage trial for bird flu vaccine - Seeking Alpha
Analyst recommendations: Meta, Amazon, Booking, Goldman Sachs, Moderna… - marketscreener.com
Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines) - marketscreener.com
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot - BioSpace
Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine - GuruFocus
Moderna begins phase 3 trial of H5 bird flu vaccine candidate - Investing.com Canada
Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - ACCESS Newswire
Moderna begins late-stage bird flu shot trial in U.S. and UK - Stock Titan
High-Yield Autocallable Notes Linked to Moderna (AMUB) — 1-Year Term - Stock Titan
Europe Clears First Flu/COVID Combo Shot From Moderna - Benzinga
Moderna Receives European Commission Marketing Authorization For mCOMBRIAX - TradingView
Moderna: Ec Granted Marketing Authorization f - Moomoo
Moderna (MRNA) Secures EU Approval for mCOMBRIAX Vaccine - GuruFocus
Moderna (MRNA) Secures EU Approval for mRNA Combination Vaccine - GuruFocus
Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
Moderna wins EC nod for mCOMBRIAX - The Pharma Letter
ESCMID Global 2026: repeat vaccination with mRNA-1010 safe and effective - Clinical Trials Arena
European Commission approves Moderna’s flu-COVID combo vaccine By Investing.com - Investing.com Canada
Moderna (MRNA.US) Receives EU Approval for Influenza and COVID-19 Combination Vaccine for Older Adults - AASTOCKS.com
Moderna wins EU nod for combined COVID, flu shot (MRNA:NASDAQ) - Seeking Alpha
European Commission approves Moderna’s flu-COVID combo vaccine - Investing.com
Cambridge drugmaker wins EU approval for combination shot amid FDA battles - The Business Journals
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - ACCESS Newswire
EU approves Moderna's dual flu-COVID vaccine - Breakingthenews.net
Moderna lines up melanoma and myeloma data for ASCO in Chicago - Stock Titan
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - ACCESS Newswire
EU clears first single-shot vaccine for flu and COVID in adults 50+ - Stock Titan
Federal Court Reportedly Halts Kennedy's Vaccine Panel, Putting COVID, Flu And RSV Shots At Risk - Benzinga
AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data - BioSpace
Moderna to Present at Upcoming Conferences in May 2026 - The Batesville Daily Guard
Moderna lines up 3 investor conference webcasts in May 2026 - Stock Titan
COVID shots, newer vaccines in limbo after US court halts Kennedy's advisory panel - marketscreener.com
GSK, Moderna Both Ordered To Provide More Info In Vax Fight - Law360
What's Pushing Moderna Stock Higher Today? - Benzinga
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines - KIMT
Moderna's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Moderna, Inc. (MRNA) Investor Outlook: Assessing the Biotech Giant Amidst Revenue Decline and Market Volatility - DirectorsTalk Interviews
COVID-19 Vaccine Market is expected to Hit US$ 29.98 billion - openPR.com
Study shows Sanofi's Nuvaxovid better tolerated than Moderna's mNEXSPIKE - marketscreener.com
Moderna Inc stock (US60770K1079): Is the post-COVID pivot strong enough to unlock sustained upside? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Respiratory Pivot Amid Vaccine Demand Shifts - AD HOC NEWS
Moderna Inc. stock (US60770K1034): Is its mRNA pivot beyond COVID strong enough for sustained growth - AD HOC NEWS
Moderna, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story - Yahoo Finance
Behavioral Patterns of MRNA and Institutional Flows - Stock Traders Daily
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe - GlobeNewswire Inc.
Moderna (MRNA) Advances Cancer Therapy Research with Promising D - GuruFocus
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting - Investing News Network
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Sale |
52.29 |
13,885 |
726,047 |
59,689 |
0.49%
2.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):